Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2625-2630

  Hosono, Yoshiki ^a   Osada, Shinji ^a   Nawa, Masahito ^a   Takahashi, Takao ^a   Yamaguchi, Kazuya ^a   Kawaguchi, Yoshihiro ^a   Yoshida, Kazuhiro ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; mTOR; ROS; Signal pathway; TS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HORMONE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P70; RAPAMYCIN; SYNTHETASE; THYMIDINE SYNTHASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THERAPY EFFECT; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUOROURACIL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77955904027     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kawamura T and Sobue T: Cancer Statistics Digest. Comparison of breast cancer mortality in five countries: France, Italy, Japan, the UK and the USA from the WHO Mortality Database(1960-2000). Jpn J Clin Oncol 35(12): 758-759, 2005.
2. Center for Cancer Control and Information Services, National Cancer Center, Japan: Vital Statistics Japan (Ministry of Health, Labour and Welfare), 2010.
3. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Eng J Med 354(3): 270-282, 2006.
4. Cheung KL: Endocrine therapy for breast cancer; an overview. Breast 16(4): 327-343, 2007. (Pubitemid 47109203)
5. Buzdar AU: Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8(4): 335-341, 2003. (Pubitemid 36934482)
6. Early Breast Cancer Trialists Collaborative Group: Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
7. The Japanese Breast Cancer Society: national breast cancer patient registration survey (Final version) 37: 11, 2006.
8. Osada S and Saji S: New approach to cancer therapy: The application of signal transduction to anticancer drug. Curr Med Chem Anti Cancer Agents 3: 119-131, 2003. (Pubitemid 36221733)
9. Nahta R and Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 26(25): 3637-3643, 2007.
10. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 16;351(9114): 1451-1467, 1998.
11. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6): 1865-1878, 2001.
12. Diaz NM: Laboratory testing for HER2/neu in breast carcinoma; an evolving strategy to predict response to targeted therapy. Cancer Control 8(5): 415-418, 2001.
13. Azim H and Azim Jr HA: Targeting Her-2/neu in breast cancer. Oncology 74: 150-157, 2008.
14. Menard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R and Cascinelli N: HER-2 positive breast carcinoma as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8: 520-525, 2002. (Pubitemid 34193972)
15. Van'TVeer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871): 530-536, 2002. (Pubitemid 34130608)
16. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182, 1987.
17. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ: Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of pten in resistance to trastuzumab. Cancer Res 69(16): 6713-6720, 2009.
18. Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F and Tanaka Y: Challenge for a better combination with basic evidence. Int J Clin Oncol 13(3): 212-9, 2008. (Pubitemid 351871900)
19. Sakashita F, Osada S, Takemura M, Imai H, Tomita H, Nonaka K, Takahashi T and Seishima M: The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. Cancer Chemother Pharmacol 62: 379-385, 2008. (Pubitemid 351871794)
20. Osada S, Saji S and Osada K: Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition. Cancer 91: 1156-1165, 2001. (Pubitemid 32295421)
21. Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F and Takahashi T: The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res 28: 45-50, 2008. (Pubitemid 351362879)
22. Osada S and Carr BI: Mechanism of novel vitamin K analog induced growth inhibition in human hepatoma cell line. J Hepatol 34: 676-682, 2001. (Pubitemid 32488782)
23. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
24. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993. (Pubitemid 23182046)
25. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 4: 337-345, 2004. (Pubitemid 38944402)
26. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E and Judson I: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595, 2008.
27. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837, 2004. (Pubitemid 38638845)
28. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK and Albrecht JH: Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 278: 3656-3663, 2003.
29. Law M, Forrester E, Chytil A, Corsino P, Green G, Davis B, Rowe T and Law B: Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexs and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66: 1070-1080, 2006. (Pubitemid 43165975)
30. Dong-Yun S, Yu-Ru D, Shan-Lin L, Ya-Dong Z and Lian W: Redox stress regulates cell proliferation and apoptosis of human hepatoma through Akt protein phosphorylation FEBS Lett 542(1-3): 60-64, 2003.
31. Osada S, Imai H, Tomita H, Tokuyma Y, Okumura N, Sakashita F, Nonoka K and Sugiyama Y: Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol 21(6): 988-993, 2006. (Pubitemid 43823283)
32. 1 phase cell cycle arrest. Oral Oncol 45: 109-115, 2009.
33. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670): 554, 2004. (Pubitemid 38541907)
34. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124(3): 471-484, 2006.
35. Yang Q and Guan KL: Expanding mTOR signaling. Cell Res 17: 666-681, 2007.
36. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712): 1098-1101, 2005.
37. Fingar DC and Blenis J: Target of rapamycin (TOR) an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23(18): 3151-3171, 2004.
38. Holz MK and Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280(28): 26089-26093, 2005. (Pubitemid 41022201)
39. Boyer J, McLean EG, Aroori S et al: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res 10: 2158-2167, 2004. (Pubitemid 38375578)
40. Yoshida K, Yamaguchi K and Osada S: Challenge for a better combination with basic evidence. Int J Clin Oncol 13: 212-219, 2008. (Pubitemid 351871900)
41. Asselin E, Mills GB and Tsang BK: XIAP regulates AKT activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862-1868, 2001.